Table 2.
Comparison of MetS (items 1 through 6) in Yucatan (Y) and Ossabaw (O) miniature swine, utility as cardiovascular disease models (items 7 and 8), and cellular or molecular characteristics (items 9 through 12)
| Characteristic | Yucatan | Ossabaw | References |
| 1. Obesity | No | O > Y | 4, 8, 9, 16, 20, 52, 83, 95; Table 1; Figure 1 |
| 2. Insulin resistance | No | Yes | 16, 19, 52, 68, 83, 96; Figure 2 |
| 3. Glucose intolerance (or impaired glucose tolerance) | No | Yes | 4, 8, 9, 15, 16, 19, 52, 62, 68, 83, 95, 96, 98; Figure 2 |
| 4. Dyslipidemia (increased LDL:HDL or LDL:total cholesterol) | Yes | Yes | 9, 15, 16, 19, 51, 52, 77, 83, 98; Table 1 |
| 5. Dyslipidemia (increased triglycerides) | No | Yes | 9, 15, 16, 19, 34, 52, 62, 77, 83, 95, 96 |
| 6. Hypertension | No | Yes | 9, 16, 19, 68, 80, 83 |
| 7. Cardiovascular disease, atherosclerosis | Yes | Yes | 4, 5, 6, 7, 9, 15, 16, 18, 19, 29, 39, 40, 42, 50, 55, 61, 62, 83, 87, 91, 92; Figures 3 through 6 |
| 8. Small stature | Yes | Yes | 8, 9, 16, 83, 95; Table 1 |
| 9. Other (for example, vascular calcification, AMP kinase alleles) | No | Yes | 42, 54, 66, 92; Figure 3 |
| 10. CSM Ca2+ efflux dysfunction | Yes | O > Y | 96, 98; Figure 7 |
| 11. CSM SERCA dysfunction | Yes | O > Y | 32, 34, 98; Figure 8 |
| 12. CSM store-operated Ca2+ entry | No | Yes | 14, 19, 31 |